MedPath

@home: a study to investigate the subjective and physiological efficacy and safety of Lybrido and Lybridos in the domestic setting in healthy female subjects with Female Sexual Dysfunctio

Completed
Conditions
Female Sexual Dysfunction (FSD), Hypoactive Sexual Desire Disorder, Female Sexual Arousal Disorder, FSD
Registration Number
NL-OMON28613
Lead Sponsor
Emotional Brain
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
120
Inclusion Criteria

For inclusion in the study, the subjects of the study group healthy women with Female Sexual Dysfunction must fulfil the following criteria:

1. Provision of written informed consent.

Exclusion Criteria

1. Use of oral contraception containing anti-androgens (Like Diane 35 or Minerva).

2. Use of oral contraception containing 50 μg estrogen or more.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate efficacy of Lybrido and Lybridos on subjective sexual experience in the domestic setting in healthy female subjects with Female Sexual Dysfunction.
Secondary Outcome Measures
NameTimeMethod
1. To evaluate efficacy of Lybrido and Lybridos on physiological sexual responding (vaginal and clitoral) in the domestic setting in different subgroups of women with FSD. <br /><br>2. To investigate differences in attentional bias for erotic stimuli in different subgroups of women with FSD, and the influence of Lybrido and Lybridos herein. <br /><br>3. To investigate differences in subjective, physiological and neuropsychological responding at home or in the laboratory. <br /><br>4. To evaluate the safety of Lybrido and Lybridos in the domestic setting.<br>
© Copyright 2025. All Rights Reserved by MedPath